HMOX1 and endothelial dysfunction: The activation of eNOS-counterpart CAV-1 and lower HO-1 levels indicate endothelial dysfunction in the RL-treated group, which was absent after EDI treatment, suggesting that the EDI may efficiently inhibit oxidative cell damage.